Introduction
Breast cancer is the most frequent malignant disease among women worldwide, but also in the Republic of Macedonia [1] [2] [3] [4] . Also, breast cancer is the leading cause of cancer mortality [1] [2] [3] [4] . Today, many factors are listed as most important ones for determining the prognosis of breast cancer, like tumour size, histologic subtype, tumour grade, lymphovascular invasion of tumour cells and axillary lymph node status. However, the presence of hormonal receptors (estrogen and progesterone) on the surface of the tumour cell, the presence of HER-2 neu receptor and other factors have been added to this list in the last twenty years [5] . Also, the biological https://www.id-press.eu/mjms/index potential for proliferation and dividing was routinely examined, represented as Ki67 value. Today, every patient that is surgically treated undergoes routine examination with standard macroscopic and microscopic histological analysis, TNM staging, staging by immunohistochemical recognition of estrogen receptors (ER), progesterone receptors (PR), the presence of HER-2 neu receptors, and the prognostic value of Ki67 [6] . Each of these parameters, alone or in combination, determines the biology and aggression of the tumour, but also gives us the opportunity to treat the given type of breast cancer properly. The combination of these parameters gives us the opportunity to determine the genetic subtype of breast cancer. According to the new classification system for breast cancer subtypes presented in St. Gallen, which we use, breast cancer is divided in Luminal A, Luminal B with HER2 negative, Luminal B with HER2 positive, HER2 enriched and basal-like (triple negative) [7] .
Analyzing the presence of breast cancer subtypes in our materials, and comparing the results with other studies to see if some subtypes in our materials differ from other studies published before, also, determining if the subtypes and the clinical stage are somehow correlated.
Material and Methods
A total of 290 patients, who were surgically treated for breast cancer at the University Clinic for Thoracic Surgery, Skopje, Republic of Macedonia were analysed during 2014, with complete history, using all parameters.
All cases underwent standard histological examination, including macroscopic and microscopic analysis with standard H&E staining. Immunohistochemical staining for ER, PgR, HER-2 and Ki-67 were performed on sections of formalinfixed paraffin-embedded tissue from the primary tumours. Pathohistological tests were conducted in three accredited laboratories (two in the Institute of Pathology at the Medical Faculty in Skopje and one in a private laboratory).
Upon microwave-pretreated in citric acid (10 mM), monoclonal mouse antibody to ER, PgR, HER-2 or Ki-67 was applied for 30 min at room temperature using the following dilutions: anti-ER-1 : 100, anti-PgR-1 : 80 (DAKO laboratories, UK); prediluted anti-HER-2 (Hercept test, DAKO Laboratories, UK); anti-Ki-67-1 : 200 (DAKO Laboratories, UK). Upon three rinses in Tris-buffered saline (TBS) and incubation with the secondary antibody, positive brown staining was detected using standard avidin and biotinylated horseradish peroxidase (ABC) technique with 3, 3′-diaminobenzidine (DAB) as the chromogen. Slides were then counterstained in Mayer's haematoxylin for 10 seconds, dehydrated in graded alcohol, mounted and scored.
Positive and negative controls were performed with each stain, and surgical specimens from the same patient were stained on the same run. 
Results
Patient's age was ranged between 18-90 years, an average of 57.6 years. The mean size of a primary tumour was 30.27 + 18.3 mm. Axillary lymph nodes metastases were detected in 59% of the patients.
We used the new St. Gallen classification system for defining breast cancer subtypes into five groups. (Table 1 ) [7] . -HER2 enriched was present in 25 (8.62%) and -Basal-like (or triple negative) was present in 27 (9.31%) patients. Many of the prognostic factors predicting the disease are very well-known, and so is their biological mode of action and how they work to spread the disease in the body. Estrogen receptors are on the surface of the tumour cell, so once estrogen binds with the estrogen receptors, it activates many processes in the cell and stimulates growth and cell division. Hence, estrogen stimulates tumour growth. Giving drugs that block estrogen receptors or drugs that block estrogen synthesis can stop the tumour growth. The same situation applies to the presence of HER-2 neu receptors. HER-2 is a membrane tyrosine kinase and oncogene that is overexpressed and gene amplified in about 20% of the breast cancer cases. When activated it provides the cell with potent proliferative and anti-apoptosis signals, and it is the major driver of tumour development and progression of breast cancer. Overexpression will activate many pathways in the cell, resulting in uncontrolled cell growth and division, causing the tumour to grow uncontrollably. Target drug delivery, monoclonal antibody trastuzumab (Herceptin), will block these receptors, and control a tumour. Moreover, giving chemotherapeutics that interact with the rapidly https://www.id-press.eu/mjms/index dividing cells will control a tumour. Ki67 is the factor that shows the proliferative activity of tumour cells. Ki67 correlates with the S phase of the cell cycle and with the mitotic activity. A normal breast cell has a proliferative activity of 3% (3% of the cells are in the dividing stage). Knowing the subtype:
we can predict the biology of a tumour and its future behaviour; -we can predict the prognosis of the disease;
we can plan a targeted therapy for some of the subtypes.
Knowing the prevalence of subtypes in one population can help plan a general therapeutic approach [16] .
Some authors define 4 subtypes: Luminal A, Luminal B, HER-2 enriched and basal cell (triple negative) (Valejos, Carey), other authors define 6 subtypes: Luminal A, Luminal B, HER2+, basal-like (triple negative), normal breast cell-like and Claudinlow (Eroles), but the most frequently used classification encompasses 5 subtypes [7] [13] [14] [17]. In practice, breast subtypes are defined by detecting the presence of estrogen, progesterone and HER-2 neu receptors on the surface of the malignant cell using immunohistochemical assays. Knowing that the presence or absence of receptors on the surface of breast cancer cell is conditioned by gene mutations and overexpression, subtypes can also be detected by assessing the gene expression. This is why the term genotype of breast cancer is cited in the literature.
The most frequent type is Luminal A which is found in 50-72% of the patients with breast cancer. Patients with this type of cancer have the best prognosis, i.e. low proliferative index, good differentiation, with the lowest risk of local recurrence and relapse [13] Luminal B subtype is characterised with positive estrogen receptors, with positive or negative HER2 receptors, with a higher Ki-67 value of over 14%, which in both types of Luminal B gives worse prognosis than Luminal A subtype.
Luminal B type is found in 10-20% of the patients with breast cancer, and in our examination, the HER-2 negative was detected in 31.38% and HER-2 positive in 24.14 % of the patients. Literature references are as follows: Italy 36%, Egypt 24.6% [24] [28] . This shows that most of the tumours in our group are aggressive. Luminal B subtype is much more aggressive than the Luminal A subtype and is characterised by poor differentiation, more frequent bone metastases and with a worse prognosis. Many authors suggest that patients in this subtype are younger patients with bigger tumours, with positive nodal status and higher N stage [16] . Given the presence of larger tumours and the advanced stage of the disease, Luminal B findings are more frequent in our study. Regarding patient's age, there was no difference found between Luminal A and Luminal B types; however, in our study, Luminal B prevailed in older patients [13] HER-2 enriched subtype is found in 15-20% of the patients. In our group, it was detected in 8.62% of the patients. This subtype is characterized by high proliferative index and poor differentiation in most of the patients, and p53 mutations are very often detected. This is a very aggressive type of a tumour, with only 12% of the patients surviving 10 years [ In our study, the triple negative was detected in 9.31% of the cases.
The suggested therapy is chemotherapy, but also PARP inhibitors (poly ADP ribosome polymerase inhibitors) like olaparib in detected BRCA1 or BRCA2 mutations [14] [15] .
The normal breast cell-like subtype that is defined by some authors is found in 5-10% of the patients. This type doesn't respond to neoadjuvant therapy, only to adjuvant chemotherapy protocol. Often, it is well-differentiated with low proliferation index and is characterised by median overall survival [14] .
We registered the difference in frequencies among our subgroups and those cited in the literature. This explains the heterogeneity of breast cancer across the world. It is cited in the literature that some subtypes are more frequent in certain races (triple negative is more frequent in African-American women) [13] [19] . Knowing the prevalence of subtypes in one population, we can plan a general therapeutic approach [16] .
There is no significant difference in age regarding subgroups of breast cancer, patients range between 52,72 and 58,83 years, except in Luminal B HER negative and HER enriched subgroups (P = 0.0255). Patient's age in subgroups of breast cancer is shown in Figure 1 .
The mean size of tumours in different subgroups ranges between 27.18 and 35 mm. The biggest tumour diameter was found in the triple negative subgroup, but there were no significant differences in the whole group, and also between subgroups. The same situation applies to the tumour diameter defined as T stage with no difference in the position between subgroups. Regarding the values of Ki67, the factor that suggests the proliferative activity of the tumour, its aggression and biology, values higher than 14% were detected in Luminal B HER negative subtype (in all patients), but also in HER-2 enriched and triplenegative subtypes. On the contrary, no values higher than 14% were detected in Luminal A subtype, which suggests that this subtype is less aggressive [13] The patterns of distribution of cells positive for estrogen, progesterone and HER-2 neu receptors were significantly different in subgroups, which is normal because we know that these receptors are main factors for defining the different subtypes of breast cancer [7] [14] . https://www.id-press.eu/mjms/index Knowing the subtype of breast cancer, in addition to the histological type and TNM stage, can suggest further prognosis of the disease, detect the spreading and find where metastases can appear later, but can also suggest further therapeutic approach [15] .
Also knowing that all factors that determine breast cancer subtypes can be evaluated from core biopsy materials before starting treatment, some subtypes (the more aggressive ones) can be treated with adequate drugs in neoadjuvant protocol [14] .
In conclusion, detecting the subtype of breast cancer is important for disease prognosis, but also for determining and providing an adequate therapy. Hence, the molecular subtype of breast cancer needs to be determined in a routine histopathological assay.
